Identifying Drug Development Opportunities for DMD with CureDuchenne

Update: 2024-08-01

Description

We love to hear from our listeners. Send us a message.

Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD). Miller and Kelly also share their advice and recommendations for companies developing drugs for DMD - while much progress has been made, more innovation is needed.

Subscribe to the podcast!
Apple | Spotify | YouTube

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Inside Gene Therapies for Cardiac Care with Tenaya Therapeutics' Faraz Ali

2025-02-1335:38

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

2025-01-3026:49

The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan

2025-01-1624:24

Lessons in Automation with Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D.

2025-01-0214:49

Can Gene Therapy Be the Solution for CHF with AskBio's Dr. Lothar Roessig

2024-12-1921:08

Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rahkit

2024-12-0531:14

Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene

2024-11-2121:39

Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

2024-11-0720:52

Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

2024-10-2425:26

Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.

2024-10-1014:18

Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge

2024-09-2522:00

A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino

2024-09-1228:06

Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts

2024-08-2925:13

CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.

2024-08-1527:58

Identifying Drug Development Opportunities for DMD with CureDuchenne

2024-08-0129:55

Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington

2024-07-1821:01

TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.

2024-07-0435:30

Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft

2024-06-2027:52

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko

2024-06-0614:52

The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley

2024-05-2825:21

00:00

Identifying Drug Development Opportunities for DMD with CureDuchenne

#box-pro-ellipsis-173972059193078{-webkit-line-clamp:2;}Identifying Drug Development Opportunities for DMD with CureDuchenne

Identifying Drug Development Opportunities for DMD with CureDuchenne

Erin Harris

Identifying Drug Development Opportunities for DMD with CureDuchenne